When.com Web Search

  1. Ads

    related to: alternative drugs to warfarin

Search results

  1. Results From The WOW.Com Content Network
  2. Direct factor Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

    The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]

  3. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. [6][7][8] It is used an alternative to warfarin to prevent blood clots following hip or knee replacement and in those with a ...

  4. Warfarin - Wikipedia

    en.wikipedia.org/wiki/Warfarin

    For the class of compounds known as "coumadins", see Coumadins. For the natural compound, see Coumarin. Warfarin, sold under the brand name Coumadin among others, is an anticoagulant medication. [ 12 ] While the drug is described as a "blood thinner", it does not reduce viscosity but rather inhibits coagulation.

  5. Dabigatran - Wikipedia

    en.wikipedia.org/wiki/Dabigatran

    Contents. Dabigatran. Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. [ 6 ][ 7 ] Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. [ 6 ] It is ...

  6. Edoxaban - Wikipedia

    en.wikipedia.org/wiki/Edoxaban

    Edoxaban. Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor. [3] It is taken by mouth. [3] Compared with warfarin it has fewer drug interactions. [6] It was developed by Daiichi Sankyo and approved in July 2011, in Japan for prevention of venous thromboembolisms following ...

  7. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

    www.aol.com/2013/01/02/us-fda-approves-eliquis...

    Purely ischemic strokes occurred with similar rates on both drugs. ELIQUIS was superior to warfarin for the primary safety endpoint of major bleeding, with a 31% relative risk reduction (2.13% ...